Abstract
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators reduce agonist-induced platelet activation and function. CFTR modulators, such as ivacaftor, present a promising therapeutic strategy in thrombocytopathies, including severe COVID-19. https://bit.ly/3HJykdt
| Original language | English |
|---|---|
| Article number | 2202009 |
| Journal | European respiratory journal |
| Volume | 61 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1 Mar 2023 |
Keywords
- COVID-19
- Cystic Fibrosis
- Cystic Fibrosis Transmembrane Conductance Regulator/genetics
- Health Status
- Humans
- Mutation
- Platelet Activation
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: European respiratory journal, Vol. 61, No. 3, 2202009, 01.03.2023.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients
AU - Asmus, Erik
AU - Karle, Weronika
AU - Brack, Markus C.
AU - Wittig, Corey
AU - Behrens, Felix
AU - Reinshagen, Leander
AU - Pfeiffer, Moritz
AU - Schulz, Sabrina
AU - Mandzimba-Maloko, Bertina
AU - Erfinanda, Lasti
AU - Perret, Paul L.
AU - Michalick, Laura
AU - Smeele, Patrick J.
AU - Lim, Endry H. T.
AU - van den Brom, Charissa E.
AU - Vonk, Alexander B. A.
AU - Kaiser, Toralf
AU - Suttorp, Norbert
AU - Hippenstiel, Stefan
AU - Sander, Leif E.
AU - Kurth, Florian
AU - Rauch, Ursula
AU - Landmesser, Ulf
AU - Haghikia, Arash
AU - Preissner, Robert
AU - Bogaard, Harm J.
AU - Witzenrath, Martin
AU - Kuebler, Wolfgang M.
AU - Szulcek, Robert
AU - Simmons, Szandor
N1 - Funding Information: Support statement: F. Behrens received funding from the Berlin Institute of Health (BIH). L. Michalick reports grants from the BIH and the German Centre for Cardiovascular Research (DZHK). A. Haghikia is participant in the BIH-Charité Advanced Clinician Scientist Pilotprogram funded by the Charité – Universitätsmedizin Berlin and the BIH and reports a research grant within the BIH and MDC Focus Area Translational Vascular Biomedicine. R. Preissner reports partial funding of this work by the German Research Foundation (KFO339, TRR295). M. Witzenrath reports grants from the German Research Foundation (SFB-TR84 C06 and C09, SFB 1449 B02), and from the German Ministry of Education and Research (BMBF) in the framework of CAPSyS (01ZX1604B, 01ZX1304B), SYMPATH (01ZX1906A), PROVID (01KI20160A), Phage4Cure (16GW0141), MAPVAP (16GW0247) and NUM-NAPKON. W.M. Kuebler reports grants from the German Research Foundation (SFB-TR84 A2 and C9, SFB 1449 B1, SFB 1470 A4, KU1218/9-1, KU1218/11-1, and KU1218/12-1), the BMBF in the framework of SYMPATH (01ZX1906A) and PROVID (01KI20160A), and the DZHK. S. Simmons reports grants from the DZHK and the German Foundation for Heart Research (F-09-19). Funding information for this article has been deposited with the Crossref Funder Registry. Funding Information: We would like to thank all medical, paramedical, laboratory and nursing staff involved in the care of the COVD-19 patients and for realising the patient recruitment at Charité – Universitätmedizin Berlin, Germany, and Amsterdam UMC, The Netherlands. F. Behrens received funding from the Berlin Institute of Health (BIH). L. Michalick reports grants from the BIH and the German Centre for Cardiovascular Research (DZHK). A. Haghikia is participant in the BIH-Charité Advanced Clinician Scientist Pilotprogram funded by the Charité – Universitätsmedizin Berlin and the BIH and reports a research grant within the BIH and MDC Focus Area Translational Vascular Biomedicine. R. Preissner reports partial funding of this work by the German Research Foundation (KFO339, TRR295). M. Witzenrath reports grants from the German Research Foundation (SFB-TR84 C06 and C09, SFB 1449 B02), and from the German Ministry of Education and Research (BMBF) in the framework of CAPSyS (01ZX1604B, 01ZX1304B), SYMPATH (01ZX1906A), PROVID (01KI20160A), Phage4Cure (16GW0141), MAPVAP (16GW0247) and NUM-NAPKON. W.M. Kuebler reports grants from the German Research Foundation (SFB-TR84 A2 and C9, SFB 1449 B1, SFB 1470 A4, KU1218/9-1, KU1218/11-1, and KU1218/12-1), the BMBF in the framework of SYMPATH (01ZX1906A) and PROVID (01KI20160A), and the DZHK. S. Simmons reports grants from the DZHK and the German Foundation for Heart Research (F-09-19). Funding information for this article has been deposited with the Crossref Funder Registry.
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Cystic fibrosis transmembrane conductance regulator (CFTR) modulators reduce agonist-induced platelet activation and function. CFTR modulators, such as ivacaftor, present a promising therapeutic strategy in thrombocytopathies, including severe COVID-19. https://bit.ly/3HJykdt
AB - Cystic fibrosis transmembrane conductance regulator (CFTR) modulators reduce agonist-induced platelet activation and function. CFTR modulators, such as ivacaftor, present a promising therapeutic strategy in thrombocytopathies, including severe COVID-19. https://bit.ly/3HJykdt
KW - COVID-19
KW - Cystic Fibrosis
KW - Cystic Fibrosis Transmembrane Conductance Regulator/genetics
KW - Health Status
KW - Humans
KW - Mutation
KW - Platelet Activation
UR - http://www.scopus.com/inward/record.url?scp=85150912834&partnerID=8YFLogxK
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85150912834&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/36958745
U2 - https://doi.org/10.1183/13993003.02009-2022
DO - https://doi.org/10.1183/13993003.02009-2022
M3 - Article
C2 - 36958745
SN - 0903-1936
VL - 61
JO - European respiratory journal
JF - European respiratory journal
IS - 3
M1 - 2202009
ER -